Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,237,304 papers from all fields of science
Search
Sign In
Create Free Account
Leishmaniasis
Known as:
Leishmaniases
, Leishmaniasis, unspecified
, leishmania infection
Expand
A parasitic infection caused by protozoa of the genus Leishmania. It is transmitted to humans via the bite of sandflies. There are three main forms…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
24 relations
Antileishmanial [EPC]
Genus: Leishmania
In Blood
Itraconazole
Expand
Broader (1)
Arthropod-borne disease, unspecified
Narrower (6)
Chiclero ulcer
Ethiopian cutaneous leishmaniasis
Leishmaniasis, Cutaneous
Leishmaniasis, Visceral
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
Shilpi Khare
,
A. Nagle
,
+34 authors
F. Supek
Nature
2016
Corpus ID: 4466686
Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide and lead to more than 50,000 deaths…
Expand
Review
2012
Review
2012
Leishmania development in sand flies: parasite-vector interactions overview
Anna Dostálová
,
P. Volf
Parasites & Vectors
2012
Corpus ID: 9573062
Leishmaniases are vector-borne parasitic diseases with 0.9 – 1.4 million new human cases each year worldwide. In the vectorial…
Expand
Highly Cited
2009
Highly Cited
2009
Molecular basis of antimony treatment in leishmaniasis.
P. Baiocco
,
G. Colotti
,
S. Franceschini
,
A. Ilari
Journal of Medicinal Chemistry
2009
Corpus ID: 1763654
Leishmaniasis is a disease that affects 2 million people and kills 70000 persons every year. It is caused by Leishmania species…
Expand
Review
2004
Review
2004
Treatment of cutaneous leishmaniasis among travellers.
J. Blum
,
P. Desjeux
,
Eli Schwartz
,
B. Beck
,
C. Hatz
Journal of Antimicrobial Chemotherapy
2004
Corpus ID: 14109996
Leishmaniasis is endemic in 88 countries on five continents. There are 1-1.5 million cases of cutaneous leishmaniasis reported…
Expand
Review
2004
Review
2004
Leishmaniasis: drugs in the clinic, resistance and new developments.
M. Ouellette
,
J. Drummelsmith
,
B. Papadopoulou
Drug resistance updates
2004
Corpus ID: 13586959
Review
2003
Review
2003
The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function.
C. Yao
,
J. Donelson
,
M. Wilson
Molecular and biochemical parasitology (Print)
2003
Corpus ID: 25496412
Review
2001
Review
2001
Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis
H. Murray
Antimicrobial Agents and Chemotherapy
2001
Corpus ID: 16140846
Visceral leishmaniaisis (kala-azar) is a disseminated protozoal infection, transmitted by sandfly bite, in which macrophages of…
Expand
Highly Cited
1996
Highly Cited
1996
Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase
S. Stenger
,
N. Donhauser
,
Heike Thiiring
,
Martin l611inghoff
,
C. Bogdan
Journal of Experimental Medicine
1996
Corpus ID: 12719187
Nitric oxide (NO) synthase (iNOS) is required for the resolution of acute cutaneous leishmaniasis in resistant C57BL/6 mice. As…
Expand
Highly Cited
1987
Highly Cited
1987
The Leishmaniases in biology and medicine
W. Peters
,
R. Killick-Kendrick
1987
Corpus ID: 90762285
The Leishmaniases in biology and medicine , The Leishmaniases in biology and medicine , مرکز فناوری اطلاعات و اطلاع رسانی کشاورزی
Highly Cited
1986
Highly Cited
1986
New perspectives on a subclinical form of visceral leishmaniasis.
R. Badaró
,
T. Jones
,
+5 authors
W. Johnson
Journal of Infectious Diseases
1986
Corpus ID: 40004072
During an epidemiological study of visceral leishmaniasis in an endemic region of Brazil, new perspectives emerged on a…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE